There are 46 papers on heterozygous familial hypercholesterolemia in aging research: 12 trials and 12 observational studies in people, 19 reviews.
46 papers study it8 more mention it6 findings
22 new papers in 30 daysSee all 54 papers on heterozygous familial hypercholesterolemia
“Normal coronary arteries were found in 161 (37.0%) patients, non-obstructive CAD in 185 (42.5%), and obstructive CAD in 89 (20.4%).”
- Human trial12
- Humans12
- In silico1
Effects
2Cataract
no changein humans1
1 study
Cataract
no changein humans1
Heterozygous familial hypercholesterolemia was not clearly linked with cataract in humans.
Humanscataract surgery used as proxy for cataract development; HeFH on statins versus relatives without hypercholesterolemia≥5 years statin treatment
PCSK9
upin humans1
1 study
PCSK9
upin humans1
Heterozygous familial hypercholesterolemia is linked with higher PCSK9 in humans.
Humansn = 255
Associations
4Coronary artery disease
upin humans1
1 study
Coronary artery disease
upin humans1
Heterozygous familial hypercholesterolemia is associated with coronary artery disease in humans (Non-obstructive CAD: 185 (42.5%); obstructive CAD: 89 (20.4%)).
HumansAsymptomatic heterozygous familial hypercholesterolemia without prior atherosclerotic cardiovascular diseasecoronary artery56% womensn = 435
Cumulative LDL-C burden
upin humans1
1 study
Cumulative LDL-C burden
upin humans1
Heterozygous familial hypercholesterolemia is associated with cumulative LDL-C burden in humans (Suspected HeFH versus non-FH participants with identical LDL-C thresholds) (102±37 vs 39.5±21 mmol/L-years; mean difference 62.5 mmol/L-years, 95% CI 42.6–82.4; 2.6-fold higher burden).
HumansSuspected HeFH versus non-FH participants with identical LDL-C thresholdsn = 16
NRP1
mixedin humans1
1 study
NRP1
mixedin humans1
NRP1 is associated with heterozygous familial hypercholesterolemia in humans (depleted samples; HeFH compared with non-FH patients during PCSK9i treatment).
Humansdepleted samples; HeFH compared with non-FH patients during PCSK9i treatmententire year of treatment
Diabetes mellitus
downin humans1
1 study
Diabetes mellitus
downin humans1
Heterozygous familial hypercholesterolemia is linked with a lower risk of diabetes mellitus in humans (HeFH vs FCH on statin therapy) (2% vs 20%, P < .001).
HumansHeFH vs FCH on statin therapy10-year follow-upn = 280
Trial sponsors
Company4 trialsPhase 41,758 people
Novartis Pharmaceuticals Corporation
Company2 trialsPhase 33,587 people
Company2 trialsPhase 3628 people
Company1 trialPhase 3482 people
Company1 trialPhase 3210 people
Company1 trialPhase 3158 people
Company1 trialPhase 384 people
Company2 trialsPhase 2/3163 people
Latest
43 papers in 12 monthsDiet quality, PCSK9 inhibitor use, and plasma lipids among adults with heterozygous familial hypercholesterolemia: a cross-sectional study
Aortic Stenosis in Familial Hypercholesterolemia: A Meta-Analysis
Real‐World Safety and Effectiveness of Evolocumab in Japanese Patients With Familial Hypercholesterolemia: Postmarketing Survey Analysis
PCSK9 Inhibitors for the Primary Prevention of Major Cardiovascular Events in High-Risk Adults Without Prior Myocardial Infarction or Stroke: A Systematic Review and Meta-Analysis
Leukogram-Derived Biomarkers and Cardiovascular Risk in Genetically Confirmed Heterozygous Familial Hypercholesterolemia
Efficacy and Safety of PCSK9 Targeting Therapies for Familial Hypercholesterolaemia in Adults and Children; a Systematic Review and Meta-Analysis
See all 54 papers on heterozygous familial hypercholesterolemia